David Tougeron/oncologypro.esmo.org
Jan 30, 2025, 05:52
David Tougeron: Great results of the BOT/BAL combination in mCRC
David Tougeron, President of the FFCD Scientific Council, shared a post on LinkedIn:
“Great results of the BOT/BAL combination in chemoresistant pMMR/MSS mCRC with no liver metastase.
- 19% ORR
- 55% DCR
Phase III is ready!”
More posts featuring David Tougeron.
Read the post “No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25” on oncodaily.com.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32